Long-term outcome after COVID-19 infection in multiple sclerosis: a nation-wide multicenter matched-control study.
Eur J Neurol
; 2022 Jun 25.
Article
em En
| MEDLINE
| ID: mdl-35751475
ABSTRACT
BACKGROUND:
Long-term outcome after COVID-19 in patients with multiple sclerosis (pwMS) is scarcely studied and controlled data are lacking.OBJECTIVE:
To compare long-term outcome after COVID-19 in pwMS to a matched control group of pwMS without COVID-19.METHODS:
We included pwMS with PCR-confirmed diagnosis of COVID-19 and ≥6 months of follow-up available and, as a control group, pwMS matched 11 for age, sex, disability level and disease-modifying treatment type.RESULTS:
Of 211 pwMS with COVID-19 (mean age 42.6 years [SD 12.2], 69% female, median EDSS 1.5 [range 0-7.5], 16% antiCD20), 90.5% initially had a mild COVID-19 course. At follow-up, 70% had recovered completely 3 months (M3) after COVID-19, 83% after 6 months (M6) and 94% after 12 months (M12). Mild initial COVID-19 course was the only significant predictor of complete recovery (odds ratio [OR] 10.5; p<0.001). Most frequent residual symptoms were fatigue (M3 18.5%, M6 13.7%, M12 7.3%), hyposmia (M3 13.7%, M6 5.2%, M12 1.7%) and dyspnea (M3 7.1%, M6 6.6%, M12 2.8%). Compared to matched controls, fatigue, hyposmia and dyspnea were significantly more frequent at M3 and still slightly at M6, while there was no difference at M12. PwMS with COVID-19 had neither a significantly increased risk for relapses (OR 1.1; p=0.70) nor disability worsening (OR 0.96; p=0.60).DISCUSSION:
Long-term outcome of COVID-19 is favourable in a large majority of pwMS with only a small proportion of patients suffering from persistent symptoms usually resolving after 3-6 months. COVID-19 is not associated with increased risk of relapse or disability.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Tipo de estudo:
Clinical_trials
/
Prognostic_studies
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article